{"doi":"10.1200/jco.20.00491","title":"Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia","abstract":"PURPOSE: The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS: This phase II study tested a combination regimen of obinutuzumab, ibrutinib, and venetoclax for a total of 14 cycles in both patients with treatment-naïve (n = 25) and relapsed or refractory (n = 25) chronic lymphocytic leukemia to determine the response to therapy and safety. RESULTS: The primary end point was the rate of complete remission with undetectable minimal residual disease by flow cytometry in both the blood and bone marrow 2 months after completion of treatment, which was 28% in both groups. The overall response rate at that time was 84% in treatment-naïve patients and 88% in relapsed or refractory patients. At that time, 67% of treatment-naïve patients and 50% of relapsed or refractory patients had undetectable minimal residual disease in both the blood and marrow. At a median follow-up of 24.2 months in treatment-naïve patients and 21.5 months in relapsed or refractory patients, the median progression-free and overall survival times were not yet reached, with only 1 patient experiencing progression and 1 death. Neutropenia and thrombocytopenia were the most frequent adverse events, followed by hypertension. Grade 3 or 4 neutropenia was experienced by 66% of patients, with more events in the relapsed or refractory cohort. There was only 1 episode of neutropenic fever. A favorable impact on both perceived and objective cognitive performance during treatment was observed. CONCLUSION: The combination regimen of obinutuzumab, ibrutinib, and venetoclax offers time-limited treatment that results in deep remissions and is now being studied in phase III cooperative group trials.","journal":"Journal of Clinical Oncology","year":2020,"id":54349,"datarank":3.811945540958811,"base_score":4.663439094112067,"endowment":4.663439094112067,"self_citation_contribution":0.6995158641168101,"citation_network_contribution":3.1124296768420012,"self_endowment_contribution":0.6995158641168101,"citer_contribution":3.1124296768420012,"corpus_percentile":null,"corpus_rank":null,"citation_count":105,"citer_count":96,"citers_with_citation_signal":88,"citers_with_endowment":88,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9454,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02427451"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":278928,"name":"Ying Huang","orcid":"0000-0001-9910-1212","position":1,"is_corresponding":false},{"id":280260,"name":"Amy S. Ruppert","orcid":null,"position":2,"is_corresponding":false},{"id":278929,"name":"Lynne V. Abruzzo","orcid":"0000-0001-6113-7447","position":3,"is_corresponding":false},{"id":278930,"name":"Barbara L. Andersen","orcid":"0000-0002-7335-1325","position":4,"is_corresponding":false},{"id":278931,"name":"Farrukh T. Awan","orcid":"0000-0003-1813-9812","position":5,"is_corresponding":false},{"id":278932,"name":"Seema A. Bhat","orcid":"0000-0001-7844-0856","position":6,"is_corresponding":false},{"id":280261,"name":"Allison Dean","orcid":null,"position":7,"is_corresponding":false},{"id":280262,"name":"Margaret S. Lucas","orcid":null,"position":8,"is_corresponding":false},{"id":280263,"name":"Christin Banks","orcid":null,"position":9,"is_corresponding":false},{"id":280264,"name":"Cara Grantier","orcid":null,"position":10,"is_corresponding":false},{"id":252809,"name":"Nyla A. Heerema","orcid":null,"position":11,"is_corresponding":false},{"id":278008,"name":"Gerard Lozanski","orcid":"0000-0002-5095-0456","position":12,"is_corresponding":false},{"id":278933,"name":"Kami J. Maddocks","orcid":"0000-0001-8519-8404","position":13,"is_corresponding":false},{"id":278934,"name":"Thomas R Valentine","orcid":"0000-0001-9415-936X","position":14,"is_corresponding":false},{"id":278935,"name":"David M. Weiss","orcid":"0000-0001-5806-4144","position":15,"is_corresponding":false},{"id":278936,"name":"Jeffrey A. Jones","orcid":"0000-0001-9557-0820","position":16,"is_corresponding":false},{"id":245731,"name":"Jennifer A. Woyach","orcid":"0000-0002-3403-9144","position":17,"is_corresponding":false},{"id":35686,"name":"John C. Byrd","orcid":"0000-0001-9830-0711","position":18,"is_corresponding":false},{"id":278927,"name":"Kerry A. Rogers","orcid":"0000-0001-5748-7874","position":0,"is_corresponding":true}],"reference_count":45,"raw_metadata":null,"created_at":"2026-07-18T21:03:43.037640Z","pmid":"32795224","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}